ArticleEuropean radiology experimental2026
Clinical feasibility of accelerated whole liver water T
Article in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCurrent liver T1 mapping methods present restricted liver coverage, take long acquisition times and mostly exclude the T1 bias induced by fat and iron effects. We evaluated the clinical feasibility of an accelerated water T1 (wT1) mapping method, including all liver segments and the potential of its T2*-compensation (wT1 MATERIALS AND
methodsForty-three patients were classified into three groups: benign without/with risk of developing fibrosis and hepatocellular carcinoma (HCC). A 9-slice accelerated single-shot spiral continuous inversion-recovery Look-Locker (CIR-LL) wT1 mapping acquisition, performed in an 11-s breath-hold, and clinical images (proton density fat fraction (PDFF), T2*, T1- and T2-weighted) were acquired for all patients. ROIs were defined on the PDFF, T2* and wT1 maps in all liver segments. wT1
resultsFor each patient group, wT1 maps presented broad liver coverage, capturing all liver segments. T2* and wT1 measurements of the benign-no-risk group were significantly correlated
conclusionThe wT1 method is feasible for fast broad liver coverage in patients with HCC or benign lesions. The segments-based wT1 RELEVANCE STATEMENT: The proposed water-specific T1 mapping method, its T2*-compensation and the inclusion of all liver segments could be clinically relevant for the tissue signal assessment of fibrotic liver segments without contrast agent administration. KEY POINTS: The developed water T1 (wT1) method enables broad liver coverage in a single 11-s breath-hold. Liver wT1 mapping and the proposed T2*-compensation (wT1
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.